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The dramatic improvement in local control of rectal cancer observed during the last decades is to be attributed to attention to
surgical technique and to the introduction of neoadjuvant therapy regimens. Nevertheless, systemic relapse remains frequent and is
currently insuﬃciently addressed. Intensification of neoadjuvant therapy by incorporating chemotherapy with or without targeted
agents before the start of (chemo)radiation or during the waiting period to surgery may present an opportunity to improve overall
survival. An increasing number of patients can nowadays undergo sphincter preserving surgery. In selected patients, local excision
or even a “wait and see” approach may be feasible following active neoadjuvant therapy. Molecular and genetic biomarkers as well
as innovative imaging techniques may in the future allow better selection of patients for this treatment option. Controversy persists
concerning the selection of patients for adjuvant chemotherapy and/or targeted therapy after neoadjuvant regimens. The currently
available evidence suggests that in complete pathological responders long-term outcome is excellent and adjuvant therapy may be
omitted. The results of ongoing trials will help to establish the ideal tailored approach in resectable rectal cancer.
1. Introduction
Significant advancements have been made during the last
decades in the treatment of rectal cancer. Once considered an
incurable disease, treatment-related morbidity andmortality
have decreased from 100% to less than 5% [1]. At the same
time, the risk of locally recurrent disease, once seen in over
30% of patients and associated with a horrible fate, has been
reduced to less than 5% in recent years. The progress in
oncological outcome has led to the observation that, very
recently, the long-term survival of rectal cancer is actually
better than that of colon cancer [2]. This progress may
be attributed to increased attention to surgical technique
and to the introduction of combined modality therapy
regimens. Nevertheless, several uncertainties persist regard-
ing neoadjuvant therapy approaches, extent and technique
of surgery, and selection for adjuvant therapy. Here, we
highlight the currently accepted standard of care in the
several steps of the patient’s treatment trajectory. Also, we
identify areas of uncertainty or controversy and identify
important ongoing clinical studies aiming to resolve these
issues.
2. Staging
The aim of staging procedures is twofold: first, to enable to
tailor the therapeutic approach to the extent of locoregional
as well as systemic disease identified and, second, to
allow prognostic stage grouping and identification of those
patients at high risk of recurrence.
General staging includes measurement of carcinoembry-
onic antigen (CEA) and CT scan of chest and abdomen.
Compared to colon cancer, the incidence of synchronous
and metachronous pulmonary metastasis is notably higher
in rectal cancer patients, a finding likely explained by the fact
that venous drainage of the mid and lower rectum is systemic
rather than portal [3–6].
Locoregional staging essentially comprises endoscopic
ultrasound (EUS) and magnetic resonance imaging (MRI).
Endoscopic ultrasound is readily available, inexpensive, and
allows accurate staging of early cancers. The sensitivity
and specificity of EUS in stage T1 and T2 tumours are
>90% and >85%, respectively, while the accuracy of EUS
to predict mesorectal nodal involvement is 70%–80% [7–9].
The disadvantages of EUS include its invasive nature and
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the inability to assess the circumferential resection margin
(CRM).
Thin-section, T2-weighted, phased-array coil MRI of
the pelvis allows excellent soft tissue spatial and contrast
resolution. The MERCURY (Magnetic Resonance Imaging
and Rectal Cancer European Equivalence) multicenter study
group examined the ability of MRI to predict extramural
invasion depth (EMD) by comparing imaging data with
histopathological analysis of the resected specimens [10].
They found that, in an analysis of 295 patients, the mean
diﬀerence between the MRI derived and histopathologically
derived EMD was only −0.05mm (95% confidence interval
−0.49–0.40), resulting in actual equivalence between MRI
and histological assessment of tumour spread. Similarly, the
same group showed that MRI is highly accurate in predicting
tumour involvement of the CRM and, thus, the likelihood of
obtaining an R0 resection when primary surgery is used [11].
Mesorectal nodal metastasis represents one of the most
powerful prognosticators in rectal cancer. Iconographic
detection of nodal positivity is hampered by the considerable
overlap in size between normal and cancer-invaded lymph
nodes. When size criteria are combined with other morpho-
logical features such as mixed intranodal signal or border
irregularity, the accuracy of MRI in predicting nodal status
may reach 85% [12]. Accuracy may be further improved
by using lymphotropic contrast agents such as ultrasmall
superparamagnetic particles of iron oxide (USPIO), which
are taken up by normal but not by tumour-invaded lymph
nodes. Several authors have succeeded in considerably
improving MRI accuracy of nodal staging with the USPIO
ferumoxtran-10 [13–15]. Lambregts et al. reported the use
of the macromolecular contrast agent gadofosveset (MS325),
which is reversibly bound to plasma albumin [16]. They
found that, using histolopathology as the standard reference,
sensitivity and specificity of nodal staging improved from
76% and 82% to 80% and 97%, respectively, compared to
standard MRI (P < 0.001).
3. Surgery
There is no doubt that the dramatic improvements in local
control of rectal cancer during the past three decades are
first and foremost due to improvements in surgical training
and attention to technique [17–20]. The basic principles
of total mesorectal excision (TME) are twofold: first, sharp
dissection between the visceral and parietal layers of the
mesorectal fascia and, second, complete excision of the
mesorectum down to the pelvic floor in mid and low
lying rectal cancer. The latter principle is based on the
seminal observations by Heald and Quirke, who noted that
the mesorectum may harbor tumour deposits up to 4 cm
distal (caudal) to the lower edge of the luminal tumour
[21–24]. In parallel, it was realized that the distal bowel
resection margin may be safely reduced to less than 10mm,
and this finding, combined with novel strategies such as
intersphincteric resection and coloanal anastomosis, has led
to a significant increase in sphincter preserving procedures
[25–29]. In patients with low lying tumours necessitating
rectal amputation, the improvements in local control have
been far less satisfying. This may be explained by an
inherently diﬀerent (namely, more invasive) tumour biology,
but surgical factors were shown to play an important part.
Indeed, when the mesorectal plane is dissected down to the
pelvic floor, one inevitably gets very close to the tumour
when it is located near the dentate line, a location where
the mesorectum becomes very thin. Investigators from the
Dutch Rectal Cancer Trial demonstrated that, compared to
anterior resection, abdominoperineal resection resulted in
a significantly higher risk of involved CRM (26.5% versus
12.6%, P < 0.001), a higher rate of tumour perforation, and
worse survival [29]. The recent introduction of “cylindrical”
resection, encompassing wide or complete removal of the
levator muscle plate en bloc with the rectal amputation
specimen, was shown to reduce the risk of CRM involve-
ment, intraoperative perforation, and local recurrence [30–
32]. In colon cancer, randomized trials have shown that,
compared to open surgery, laparoscopic- or laparoscopy-
assisted approaches are associated with significant functional
advantages while cancer recurrence rates are similar [33, 34].
In rectal cancer, where preservation of the intact mesorectal
envelope is of critical importance, the feasibility and safety of
laparoscopic resection were suggested in several small trials
[35]. The oncological equivalence of laparoscopic versus
open rectal cancer surgery will need to be demonstrated
by the ongoing prospective randomized trials: COLOR
II, Japanese JCOG 0404, and ACOSOG Z6051 [36–38].
Preliminary results from the COLOR II trials were recently
reported [39]. A total of 1103 patients were randomized to
either laparoscopic or open rectal cancer surgery in a 2 : 1
ratio. No diﬀerences were observed in circumferential or
distal margin, anastomotic leakage rate (8.8% versus 10%
after laparoscopic versus open surgery, resp.; P = 0.63), or
nodal count. However, the laparoscopic approach resulted
in less blood loss, less analgesic use, quicker return of GI
function, and shorter hospital stay. Conversion to open
surgery was required in 16% of the patients allocated to
laparoscopic surgery. Clearly, when confirmed by long-term
oncological equivalence, the laparoscopic approach may be
advised in selected patients.
For most patients, avoidance of a permanent colostomy
in low lying tumours is a concern. The introduction of long-
term neoadjuvant chemoradiation followed by downsizing of
the tumour allows to achieve sphincter preservation in many
cases. In parallel, the technique of intersphincteric resection,
colonic pull through, and manual coloanal anastomosis
has gained popularity in low lying cancers. It has been
shown that, in contrary to mesorectal distal tumour spread,
infiltration of the rectal wall distally from the macroscopic
lower tumour border is very uncommon and, consequently,
a distal resection margin of 10mm does not compromise R0
resection. Bujko and coworkers performed ameta-analysis of
17 studies reporting local recurrence rate according to distal
resection margin (less than versus at least 1 cm) and found
no statistically significant diﬀerence in local recurrence rate
or overall survival [19]. It is clear, however, that functional
results are potentially much worse after coloanal anastomosis
and careful preoperative counseling is therefore mandatory,
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specifically in the elderly or those with preexisting impaired
continence [29, 40].
4. Neoadjuvant Radiation and Combined
Modality Therapy
Significant advances have been made in local control of
advanced rectal cancer by combining surgery with either pre-
or postoperative radiation therapy (RT). A meta-analysis
based on individual patient data (IPD) published in 2001
showed that preoperative RT reduced the yearly risk of local
recurrence with 46% (P = 0.00001), while postoperative RT
reduced the risk with 37% (P = 0.002) [41]. Overall survival,
however, was only marginally improved (62% versus 63%;
P = 0.06). From a theoretical point of view, preoperative
RT is associated with several advantages compared to the
postoperative approach. First, RT will be more active in
surgically undisturbed, well-oxygenized tissue. Second, only
the preoperative approach may result in downstaging and
downsizing eﬀects. Third, postoperative RT administration
may be hampered by compliance issues in the postoperative
setting and may lead to increased radiation damage to the
small bowel. Superiority of preoperative to postoperative
chemoradiation was demonstrated by the German rectal
cancer trial, showing that the preoperative approach resulted
in improved local control and less toxicity, but no diﬀerence
in overall survival was noted [42].
Importantly, it has been shown that protracting RT dura-
tion shifts the dose-response curve that describes control
of subclinical pelvic tumour deposits to the right, resulting
in a higher dose required to exert a similar reduction in
pelvic relapse rate [43]. A recent meta-analysis and meta-
regression related the biologically equivalent dose (BED) and
fractionation schedule of preoperative RT to survival, local
control, and sphincter preservation rate in rectal cancer [44].
It was found that, when a BED of more than 30 Gray is used,
both short-term and long-term RT schedules were eﬀective
in improving local control and survival, while only a long-
term schedule resulted in increased sphincter preservation.
The Dutch randomized rectal cancer trial showed that pre-
operative short-term RT is eﬀective even when standardized,
quality-controlled TME surgery is routinely used [45]. The
recently published 12-year update from this trial confirmed
a significant reduction in local recurrence rate (5% after RT
followed by surgery versus 11% in the surgery alone group,
P < 0.0001) [46]. Of note, the results of this trial also
showed that, in patients with involved resection margins,
preoperative RT cannot prevent local recurrence [47].
There are sound theoretical arguments for combining RT
with chemotherapy. First, several chemotherapeutic agents
act as radiosensitizers and will enhance the pathological
eﬀects of RT. Second, early incorporation of chemotherapy
might address concurrent systemic disease. Several prospec-
tive randomized trials have compared preoperative RT alone
with preoperative chemoradiation (CRT) in locally advanced
rectal cancer (Table 1). The results of the completed tri-
als and ongoing studies with preliminary results may be
summarized as follows: compared to RT alone, preoperative
CRT improves pathological response and local control but is
associated with more pronounced treatment-related toxicity.
In addition, CRT does not benefit sphincter preservation rate
or long-term survival rate [48]. Debate persists regarding
the place of short course RT (SCRT) schedules (usually
5 × 5 Gray) followed by immediate surgery. Arguments
in favour include (1) the fact that SCRT has been tested
and found to be eﬀective in multiple randomized trials,
(2) convenience for the patient, and (3) the similarity in
long-term outcome when compared with long-term (C)RT
schedules. Disadvantages of SCRT include significant early
and delayed toxicity (including secondary malignancies)
observed in the Swedish and Dutch rectal cancer trials, and
the inability to achieve downstaging and downsizing when
immediate surgery (within 5–10 days) is performed [49–52].
It should be noted, however, that with modern conformal
RT delivery techniques the diﬀerences in toxicity between
SCRT and long schedule RT schedules seem minimal. An
important question is whether a longer waiting period after
SCRT would achieve pathological downstaging to the extent
observed with long-term schedules. The interim results from
the trial reported by Latkauskas et al., who randomized
patients to receive either SCRT or CRT and included a six
weeks waiting period in both groups, demonstrated a far
superior pathological response in the group who underwent
chemoradiation [53]. Additional answers are awaited in
this regard from the ongoing Stockholm III trial, which
randomizes patients to receive either SCRT with immediate
surgery, SCRTwith delayed (after 4–8 weeks) surgery, or long
course radiotherapy (25× 2 Gray) with delayed surgery [54].
Incorporation of additional chemotherapy agents in
preoperative regimens, aiming at further enhancing patho-
logical response whilst possibly improving overall survival,
seemed a rational step. Several phase III trials have been
initiated incorporating oxaliplatin, an agent which is active
in the adjuvant and palliative setting, in CRT regimens.
From four of these trials, interim data are available (Table 2).
The first results of the PETACC-6 trial, which randomizes
patients to preoperative RT (50.4 Gray in 25 fractions)
with capecitabine alone or with capecitabine + oxaliplatin
(50mg/m2), are awaited. The available results from the other
four trials suggest that the expectation of an increased patho-
logical response by adding oxaliplatin to the CRT regimen
was not fulfilled; only in the German CAO/ARO/AIO-04 trial
a significantly diﬀerent pathological complete response rate
was observed in favour of the arm containing oxaliplatin
[55]. Moreover, incorporation of oxaliplatin resulted in
significantly higher rates of grade 3 and 4 treatment-related
toxicity in three out of four trials that have reported on these
data [56–58].
There is a sound theoretical rationale to combine pre-
operative CRT with each of the targeted agents approved
for use in metastatic colorectal cancer (mCRC): cetuximab,
panitumumab, and bevacizumab. Epidermal growth factor
receptor (EGFR) signaling is associated with proliferation,
invasiveness, and metastasis. Several arguments suggest a
potential synergism between EGFR inhibition and RT. First,
EGFR tyrosine kinase activity is increased in cancer cells in
response to RT, and addition of exogenous EGF can induce
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Table 2: Interim results of randomized trials incorporating oxaliplatin in preoperative chemoradiation regimens.
Study Treatment N RT dose (Gy)
Total/per fraction
pCR SPS
STAR01 [56]
5-FU CIV 379 50.4/1.8 16% 80%
5-FU CIV + OX 60mg/m2 368 50.4/1.8 16% 82%
ACCORD 12/0405-Prodige 2 [57]
CAP 800mg/m2 299 45/1.8 13.9% 75%
CAP 800mg/m2 + OX 50mg/m2 299 50/1.8 19.2% 75%
CAO/ARO/AIO-04 [55]
5-FU; adj 5-FU 637 50.4/1.8 13.1% 88.1%
5-FU + OX 50mg/m2; adj FolFox6 628 50.4/1.8 17.6% 87.8%
NSABP R-04 [58]
5-FU CIV ± OX 50mg/m2 719 50.4/1.8 18.8% 61.2%
CAP 825mg/m2± OX 50mg/m2 707 50.4/1.8 22.2% 62.7%
CAP: capecitabine; RT: radiotherapy; pCR: pathological complete response; SPS: sphincter preserving surgery.
radioresistance in vitro [70]. Second, elevated levels of EGFR
expression are an independent adverse prognostic factor in
rectal cancer patients [71]. Numerous phase I/II trials have
studied incorporation of cetuximab in preoperative CRT
schedules. The early results regarding pathological response
(pCR rate) are disappointing [72–75]. Interestingly, KRAS
mutation, known to be an adverse predictive and prognostic
marker in mCRC patients treated with EGFR inhibitors,
is less frequent in rectal cancer and does not convey the
same predictive information [76, 77]. The recently reported
randomized EXPERT-C trial allocated high-risk rectal cancer
patients to four cycles of capecitabine/oxaliplatin (CAPOX)
followed by capecitabine CRT, TME surgery, and adjuvant
CAPOX or the same regimen plus cetuximab [78]. The pri-
mary endpoint was complete (pathological or radiological)
response in KRAS/BRAF wild-type tumours. Addition of
cetuximab did not aﬀect complete response rate or pro-
gression free survival, although it did improve radiological
response and overall survival (hazard ratio 0.07–0.99; P =
0.034).
In parallel, eﬀorts have started to combine preoperative
CRT regimens with the antiangiogenic agent bevacizumab.
Therapy directed against the vascular endothelial growth
factor (VEGF) causes “normalization” of the tumour vascu-
lar bed, that is, the return to a functionally and morpho-
logically less deficient microvascular network [79, 80]. This
phenomenon is accompanied by increased oxygenation and
a decrease in tissue interstitial fluid pressure (IFP). Moreover,
it was shown in vitro that RT induces tumour VEGF expres-
sion and protects tumour blood vessels from RT-mediated
cytotoxicity [81]. Numerous phase I/II trials have studied the
integration of bevacizumab into CRT regimens [82–91]. The
addition of bevacizumab appears to enhance pathological
response rates but is associated with increased treatment
related and postoperative complications including wound
dehiscence, bowel perforation, and bleeding [92, 93]. Of
note, several imaging (blood flow, perfusion) and molecular
biomarkers (soluble VEGF receptor, VEGF, placental derived
growth factor, IL-6, and circulating endothelial cells) were
shown to correlate with outcome after bevacizumab-based
combined modality therapy [91].
5. Novel Chemotherapy Treatment Strategies
A consistent finding of the myriad of neoadjuvant radiother-
apy containing trials is that hardly any progress has been
made in improving overall survival. Consequently, strategies
are investigated that aim at delivering more eﬃcient systemic
therapy early in the course of therapy. These strategies
include induction chemotherapy followed by CRT, and CRT
followed by consolidation chemotherapy in the waiting
period to surgery. Intensive preoperative chemotherapy not
only has the potential to eradicate subclinical metastatic
disease but also avoids the inherent compliance problems of
postoperative chemotherapy. Several phase II trials have now
generated results of neoadjuvant chemotherapy (NACT)
followed by CRT (Table 3). Although the survival data
seem promising, the two randomized phase II studies
comparing upfront CRT with NACT followed by CRT
failed to demonstrate improvements in either pCR rate or
R0 resection probability [94, 95]. Investigators from the
AVACROSS study, who incorporated bevacizumab in both
the NACT and CRT regimens, found an impressive pCR
rate 36% while 98% of patients were able to undergo an
R0 resection [96]. However, with a reoperation rate of 24%
and anastomotic leakage rate of 17%, surgical morbidity
appears a significant problemwhen intensifying preoperative
regimens with antiangiogenic agents.
An alternative approach is to administer “consolidation”
chemotherapy during the waiting period to surgery. Pre-
liminary data were provided by Habr-Gama et al., who
treated rectal cancer patients with 54Gy of RT with 5-
FU/leucovorin followed by an additional three cycles of 5-
FU/leucovorin; clinical response was assessed ten weeks after
completion of CRT [97]. Fourteen out of 29 patients (48%)
were found to have a complete clinical response, while an
additional 17% had a ypT0 stage after local excision. Garcia-
Aguilar and coworkers in a nonrandomized phase II trial
compared 5-FU based neoadjuvant CRT with a regimen
that added two cycles of FolFox in patients who had a
clinical response four weeks after CRT [98]. They found a
modest increase in pCR rate (25% versus 18%); whether
this is an eﬀect of prolonging the waiting period from 6
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to 11 weeks or of the consolidation chemotherapy cannot
be discerned. Important answers will be provided by the
ongoing phase III RAPIDO trial (NCT01558921), which
will randomize high-risk rectal cancer patients to undergo
either neoadjuvant SCRT followed by six cycles of CapOx, or
standard neoadjuvant chemoradiation. Intriguingly, recent
reports suggest that modern neoadjuvant combination
chemotherapy may result in eﬀective downstaging even
without any radiotherapy. Schrag reported on a group of
patients with resectable rectal cancer who received induction
chemotherapy (FolFox with bevacizumab) and were planned
to undergo additional CRT or immediate surgery depending
on clinical regression [99]. Interestingly, all of the 29
treated patients underwent surgery without CRT and an
impressive pCR rate of 27% was noted. No local recurrences
were observed, and three patients (10%) developed distant
metastases (all pulmonary).
6. Adjuvant Chemotherapy
At present, it is unclear how patients who underwent
neoadjuvant combined modality therapy should be selected
for adjuvant chemotherapy. In contrast to colon cancer, there
are no randomized adjuvant therapy trials in rectal cancer.
A recent Cochrane meta-analysis, based on data concerning
patients from trials including both colon and rectal cancer,
showed that 5-FU-based adjuvant chemotherapy following
curative resection of rectal cancer confers a significant
advantage in terms of overall (HR = 0.83, 95% CI: 0.76–0.91)
and disease-free (HR = 0.75, 95% CI: 0.68–0.83) survival
although significant heterogeneity between trials was noted
[118]. Unfortunately, due to limitations of the source data,
the authors were unable to identify those TNM stages
that benefit most from adjuvant chemotherapy. One of the
included trials in the Cochrane meta-analysis assigned colon
and rectal cancer patients at low risk of recurrence (90% stage
II) to either adjuvant 5-FU/folinic acid or observation [119].
Interestingly, planned subgroup analysis showed that the
relative risk of recurrence within 2 years was lower in rectal
cancer (29% of patients) than in colon cancer patients (RR
0.38–0.89 and 0.54–0.92, resp.). Based on these data, it seems
reasonable to oﬀer adjuvant chemotherapy to rectal cancer
patients based on similar criteria as in colon cancer. However,
matters are complicated by the fact that nowadays most
rectal cancer patients are treated with neoadjuvant regimens,
and uncertainty persists regarding the benefit of adjuvant
therapy in patients who have a complete or near complete
pathological response. On the one hand, patients with a
pathological complete response have a significantly better
outlook. In a recent pooled analysis using individual patient
data, 5-year disease-free survival was 83.3% for patients
with pCR and 65.6% for those without pCR (HR 0.44,
95% CI 0.34–0.57; P < 0.0001) [120]. On the other hand,
(unplanned) subgroup analysis of the four-arm EORTC
22921 trial suggested that, while adjuvant chemotherapy did
not aﬀect outcome in the whole study population irrespec-
tive of whether preoperative RT or CRT was administered,
adjuvant chemotherapy significantly improved survival in
ypT0-2 patients (but not in ypT3-4) [121]. However, the
generalizability of this finding has been questioned on
methodological grounds; moreover, in none of the other
three randomized trials exploring adjuvant chemotherapy in
patients who received preoperative (C)RT has any benefit
been detected [119, 122–124]. Clearly, therefore, the role
of 5-FU-based adjuvant therapy in patients who received
chemotherapy containing neoadjuvant regimens remains
undefined. Only one prospective randomized trial (SCRIPT,
Simply Capecitabine in Rectal cancer after Irradiation Plus
TME surgery) by the Dutch colorectal cancer group is testing
adjuvant chemotherapy versus observation in rectal cancer
patients who received neoadjuvant RT or CRT.
7. Innovation in Radiation Techniques
One of the insights gained in the radiobiology of rectal
cancer over the past years is that a biologically eﬀective
dose (BED) of at least 30 Gray needs to be administered
in order to aﬀect the risk of local recurrence [43, 125].
The pathological complete response rates obtained with
modern chemoradiation schedules are in the order of 10–
15%. Eﬀorts have been directed to enhance the therapeutic
index of radiotherapy by increasing conformity to the
target tissue. Highly conformal techniques such as intensity
modulated radiotherapy (IMRT), intensity modulated arc
therapy (IMAT), and tomotherapy were shown to result in
clinically significant reductions in GI toxicity by limiting the
dose delivered to the small bowel [126–130]. An interesting
option is endocavitary contact radiotherapy, which may
completely sterilize early (T1N0 and T2N0) rectal tumours
and was shown to result in significant improvements in
pCR and sphincter preservation rates when combined with
external beam radiotherapy [131–134]. The technique had
fallen into disuse over the last years due to the fact that
the apparatus was no longer produced. Recently, however,
another manufacturer has brought a novel machine on
the market (Papillon 50, Ariane Medical Systems, Derby,
UK). Several international trials (Contact EndoscopicMicro-
surgery, CONTEM 1–3) were recently initiated using a
combination of contact endocavitary RT with transanal
microsurgery, CRT, or standard TME in patients with T1, T2,
or early T3 rectal tumours [135, 136].
8. Organ Preservation in Rectal Cancer
In analogy to current practice in cancer of the anal canal,
definitive chemoradiation combined with local excision or
without further surgery is under active scrutiny [137, 138].
There are, nevertheless, several major hurdles to be taken
before the concept of organ preservation will gain wide
acceptance. First, clearly the adenocarcinoma of the rectum is
amuch less radiosensitive tumour, and pathological response
rates tend to be even lower in general practice compared to
what is achieved in the setting of clinical trials [139]. Second,
clinical as well as endoscopic and iconographic restagings
after CRT are notoriously unreliable, and even post-CRT
biopsies are inaccurate in predicting sterilization of both
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the tumour and the mesorectal nodes [140–143]. Clearly,
therefore, a mere “wait and see” approach should currently
only be considered in patients unfit for or refusing surgery.
There may be a role for local excision in patients who have
a substantial clinical response after chemoradiation. Several
retrospective reports and small prospective trials have shown
impressive pCR rates in early rectal cancers, while both local
control and long-term survivals seem excellent (Table 4).
Although local excision techniques certainly present less
surgical risks compared to resectional procedures, it should
be emphasized that they may carry their own specific
morbidity such as significant pain after TEM [144]. Also, the
results of these preliminary data based on a highly selected
population need to be confirmed in prospective controlled
trials. The multicenter CARTS trial in The Netherlands will
investigate the feasibility of neoadjuvant CRT (25 fractions
of 2Gy with concurrent capecitabine) followed by transanal
endoscopic microsurgery (TEM) in patients with clinical
stage T1-3, N0 rectal cancer below 10 cm from the anal
verge [145]. The French multicenter Groupe de Recherche
Chirurgicale sur le Cancer du Rectum (GRECCAR) 2 trial
(NCT00427375) will treat rectal cancer patients with a tumor
4 cm or less in diameter with neoadjuvant CRT. After a 6–
8-week waiting period, patients in whom the tumour has
downstaged to 2 cm or less will be allocated the either local
excision or TME. A polish multicenter trial (NCT00738790)
will randomize patients with cT1-3, N0 rectal cancer patients
to either short course RT (5 × 5Gy with a 4Gy boost after
1 week) or CRT followed by local excision after 6 weeks. A
Spanish trial (NCT01308190) will compare in a randomized
trial primary TME with CRT followed by local excision in
patients with clinically staged T2 or superficial T3 low rectal
cancer.
Clearly, the adaptation of local resection strategies will
depend on our ability to predict the extent of pathological
response using clinical, molecular, and imaging biomarkers.
Novel imaging techniques such as diﬀusion-weighted mag-
netic resonance imaging hold promise in the identification
of responders [146–151]. Similarly, gene expression profiling
has recently been successfully used to predict pathological
response to CRT. Ghadimi et al., using cDNA material
obtained during the German CAO/ARO/AIO-94 trial, found
that a 54 gene signature correctly predicted response in
83% of patients [152]. Similar results were reported by
Brettingham-Moore and coworkers, although this group
was unable to validate previously published gene expression
based classifiers in their patient cohort, illustrating the
diﬃculty in comparing and generalizing the use of these
classifiers due to the high dimensionality of the data
[153]. Several other molecular, genetic, and chromosomal
biomarkers of response to CRT in rectal cancer have been
identified, and these biomarkers are increasingly integrated
into clinical trial design [154–160].
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